Valuation TAUNS Laboratories,Inc.
Stocks
197A
JP3452250008
Medical Equipment, Supplies & Distribution
|
Market Closed -
Japan Exchange
02:30:00 2026-08-14 EDT
|
5-day change | 1st Jan Change | ||
| 487.00 JPY | +1.67% |
|
+4.06% | -4.32% |
| 08-13 | TAUNS Laboratories,Inc. Reports Earnings Results for the Full Year Ended June 30, 2026 | CI |
| 07-14 | Callisto Inc. announced that it expects to receive funding from TAUNS Laboratories,Inc. | CI |
Company Valuation: TAUNS Laboratories,Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 41,000 | 55,086 | 51,959 | - | - |
| Change | - | 34.36% | -5.68% | - | - |
| Enterprise Value (EV) 1 | 41,114 | 60,244 | 59,953 | 60,713 | 59,739 |
| Change | - | 46.53% | -0.48% | 1.27% | -1.61% |
| P/E | 7.1x | 8.67x | 9.79x | 14.4x | 12.9x |
| PBR | 3x | 3.15x | 2.64x | 2.56x | 2.44x |
| PEG | - | 1.16x | -0.5x | -0.4x | 1.1x |
| Capitalization / Revenue | 2.22x | 2.96x | 3.52x | 2.7x | 2.49x |
| EV / Revenue | 2.23x | 3.23x | 4.06x | 3.15x | 2.86x |
| EV / EBITDA | 4.72x | 6.71x | 11.9x | 9.3x | 8.43x |
| EV / EBIT | 5.12x | 7.29x | 15.6x | 12.6x | 11.1x |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | 21.75 | 28 | 35.28 | 28 | 28 |
| Rate of return | 5.3% | 5.2% | 7.24% | 5.75% | 5.75% |
| EPS 2 | 57.74 | 62.07 | 49.72 | 33.75 | 37.75 |
| Distribution rate | 37.7% | 45.1% | 71% | 83% | 74.2% |
| Net sales 1 | 18,435 | 18,628 | 14,756 | 19,252 | 20,884 |
| EBITDA 1 | 8,706 | 8,980 | 5,053 | 6,531 | 7,085 |
| EBIT 1 | 8,030 | 8,265 | 3,846 | 4,833 | 5,387 |
| Net income 1 | 5,774 | 6,315 | 5,201 | 3,593 | 4,019 |
| Net Debt 1 | 114.1 | 5,157 | 7,994 | 8,755 | 7,780 |
| Reference price 2 | 410.00 | 538.00 | 487.00 | 487.00 | 487.00 |
| Nbr of stocks (in thousands) | 100,000 | 102,391 | 106,692 | - | - |
| Announcement Date | 8/13/24 | 8/13/25 | - | - | - |
1JPY in Million2JPY
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 9.79x | 4.06x | 11.87x | 7.24% | 327M | |
| -48.95x | 16.01x | -116.7x | -.--% | 21.1B | |
| 17.9x | 1.99x | 8.4x | 1.43% | 9.96B | |
| -75.38x | 11.01x | -100.77x | -.--% | 7.31B | |
| 20.07x | 4.25x | 11.74x | - | 6.59B | |
| 159.38x | 5.59x | 31.45x | -.--% | 6.16B | |
| 21.71x | 7.53x | 16.91x | 2.65% | 5.97B | |
| 21.55x | 3.56x | 11.03x | 1.75% | 4.27B | |
| 16.96x | - | - | 3.79% | 2.85B | |
| Average | 15.89x | 6.75x | -15.76x | 2.11% | 7.17B | |
| Weighted average by Cap. | -0.28x | 9.11x | -43.65x | 0.88% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 197A Stock
- Valuation TAUNS Laboratories,Inc.
Select your edition
All financial news and data tailored to specific country editions
